Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

07. Januar 2019 09:00 ET | Quelle: Ascendis Pharma A/S

Ascendis Pharma A/S Introduces Vision 3x3: A Strategic Roadmap Through 2025 to Achieve Sustainable Growth Using Multiple Approaches

COPENHAGEN, Denmark, Jan. 07, 2019 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to address significant...
21. Dezember 2018 16:01 ET | Quelle: Ascendis Pharma A/S

Ascendis Pharma A/S Announces Participation in 37th Annual J.P. Morgan Healthcare Conference

COPENHAGEN, Denmark, Dec. 21, 2018 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technology to address significant unmet...
28. November 2018 16:05 ET | Quelle: Ascendis Pharma A/S

Ascendis Pharma A/S Reports Third Quarter 2018 Financial Results

- TransCon CNP preliminary phase 1 data support target product profile and further validates TransCon™ technology - - Diversified pipeline with three independent, clinically-validated rare disease...
28. November 2018 16:01 ET | Quelle: Ascendis Pharma A/S

Ascendis Pharma A/S Announces Positive Preliminary Phase 1 Data for TransCon CNP

- TransCon CNP delivered continuous exposure of CNP at target levels for seven days with a single subcutaneous administration - - TransCon CNP phase 1 results reinforce preclinical data and support...
14. November 2018 16:15 ET | Quelle: Ascendis Pharma A/S

Ascendis Pharma A/S Announces Third Quarter 2018 Financial Results and Business Update Conference Call on November 28

COPENHAGEN, Denmark, Nov. 14, 2018 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq:ASND), a biopharmaceutical company that utilizes its innovative TransCon technology to address significant unmet...
08. November 2018 16:48 ET | Quelle: Ascendis Pharma A/S

Ascendis Pharma Announces Formation of VISEN Pharmaceuticals to Develop and Commercialize TransCon™ Endocrinology Rare Disease Therapies in China

- 50/50 joint venture with investor syndicate led by Vivo Capital – - Expands global reach for TransCon products – COPENHAGEN, Denmark, Nov. 08, 2018 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S...
02. November 2018 09:00 ET | Quelle: Ascendis Pharma A/S

Ascendis Pharma A/S Announces Upcoming Investor Presentations

COPENHAGEN, Denmark, Nov. 02, 2018 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technology to address significant unmet...
17. September 2018 16:10 ET | Quelle: Ascendis Pharma A/S

Ascendis Pharma A/S Announces Support for Children’s Growth Awareness Week and Day 2018

COPENHAGEN, Denmark, Sept. 17, 2018 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technology to address significant unmet...
06. September 2018 16:02 ET | Quelle: Ascendis Pharma A/S

Ascendis Pharma A/S Announces Presentations on Technology and Rare Disease Endocrinology Pipeline at September Conferences

COPENHAGEN, Denmark, Sept. 06, 2018 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technology to address significant unmet...
31. August 2018 16:01 ET | Quelle: Ascendis Pharma A/S

Ascendis Pharma A/S Announces Upcoming Investor Presentations

COPENHAGEN, Denmark, Aug. 31, 2018 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon technology to address significant unmet...

Vorherige Seite